An announcement from LBT Innovations Limited ( ($AU:CC5) ) is now available. Clever Culture Systems Ltd has issued 2,500,000 fully paid ordinary ...

– In Ongoing Phase 1/2 Study, Single Subcutaneous Doses of ALN-CC5 Achieve Potent, Statistically Significant, and Highly Durable C5 Knockdown of up to 96% – – After Single Dose, ALN-CC5 Also Achieves ...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, and collaborators today presented initial results from Part C of its ongoing ...

HYANNIS -- In recognition of Military Family Month, Cape Cod 5 (CC5) on Friday announced a $25,000 donation to Cape and Islands Veterans Outreach Center to help fund its new Veterans Home in Dennis, ...

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings.

SAN JOSE, Calif., Aug. 28, 2025 /PRNewswire/ -- Reallusion officially releases Character Creator 5 (CC5), a major upgrade that brings the character creation ecosystem into the HD era. Its powerful ...

Alnylam Pharmaceuticals, Inc. ALNY announced initial positive results from an ongoing phase I/II study on ALN-CC5. ALN-CC5 is an investigational RNA interference (RNAi) therapeutic targeting ...

What is the current share price of Clever Culture Systems Limited (CC5)? Clever Culture Systems Limited's (CC5) current share price is $0.02. This constitutes a price movement of 0% when compared to ...

Alnylam Pharmaceuticals, Inc. has announced new pre-clinical results with its Development Candidate (DC) for ALN-CC5, a subcutaneously administered investigational RNAi therapeutic targeting ...

Alnylam Scientists Present Pre-clinical Data with ALN-CC5, an RNAi Therapeutic Targeting Complement Component C5 for the Treatment of Complement-Mediated Diseases – New Research Presented at 6 th ...

As of 7:37:42 CET. Market open.

CAMBRIDGE, Mass.--Alnylam Pharmaceuticals, Inc. (Nasdaq:ALNY), a leading RNAi therapeutics company, today announced initial positive results from its ongoing Phase 1/2 clinical trial with ALN-CC5, an ...